Holen Sie sich die Stockscreener-App
83.92
2.01%
-1.77
Schlusskurs vom Vortag:
$85.69
Offen:
$86.49
24-Stunden-Volumen:
107.66K
Relative Volume:
0.20
Marktkapitalisierung:
$5.58B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-21.52
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
+3.76%
1M Leistung:
+11.17%
6M Leistung:
+10.72%
1J Leistung:
+5.19%
1-Tages-Spanne:
$83.56
$86.49
1-Wochen-Bereich:
$80.02
$86.83
52-Wochen-Spanne:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Vergleichen Sie NUVL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
84.07 | 5.89B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.89 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.12 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
319.18 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
570.17 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.87 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Is Nuvalent Inc. a good long term investmentOutstanding capital appreciation - Jammu Links News
What drives Nuvalent Inc. stock priceExceptional earning trajectories - Jammu Links News
How high can Nuvalent Inc. stock price go in 2025Proven High Yield Signals - Newser
Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest
Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World
Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser
How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser
What makes Nuvalent Inc. stock price move sharplyFree Access to Stock Community - Newser
Recent Analysts’ Ratings Updates for Nuvalent (NUVL) - Defense World
Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock - Defense World
Nuvalent's Insider Sales and Clinical Milestones: A Balancing Act for Investors - AInvest
Nuvalent(NUVL) Shares Soar 3.47% on Positive Lung Cancer Data - AInvest
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead - Investing.com
Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - Insider Monkey
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
Nuvalent (NUVL) Gets a Buy from Goldman Sachs - The Globe and Mail
Nuvalent (NASDAQ:NUVL) Upgraded at The Goldman Sachs Group - Defense World
Goldman Sachs initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com India
Nuvalent chief development officer Noci sells $314k in shares - Investing.com
Barclays Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail
Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader - insights.citeline.com
Nuvalent stock price target raised to $114 from $100 at UBS - Investing.com
Transcript : Nuvalent, Inc.Special Call - MarketScreener
Nuvalent Reports Positive Pivotal Data From ARROS-1 Study Of Zidesamtinib - Nasdaq
Breakthrough Data Coming: Nuvalent's ROS1 Inhibitor Results in Treatment-Resistant Lung Cancer - Stock Titan
Nuvalent Appoints Christy Oliger to Board of Directors - The Malaysian Reserve
Nuvalent appoints former Genentech oncology executive to board - Investing.com
Nuvalent appoints Christy Oliger to board of directors - MarketScreener
Nuvalent Adds Former Genentech Oncology SVP to Board Ahead of 2026 Launch Plans | NUVL Stock News - Stock Titan
Nuvalent’s SWOT analysis: biotech stock poised for pivotal year in NSCLC treatment - Investing.com
GAMMA Investing LLC Boosts Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
(NUVL) Long Term Investment Analysis - news.stocktradersdaily.com
Rhumbline Advisers Acquires 2,572 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: brain-penetrant TKIs poised to reshape NSCLC stock - Investing.com India
Nuvalent board member Emily Conley resigns - Investing.com India
Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results - Seeking Alpha
Nuvalent board member Emily Conley resigns By Investing.com - Investing.com Nigeria
Nuvalent Board Member Emily Conley Resigns - TipRanks
How the (NUVL) price action is used to our Advantage - news.stocktradersdaily.com
Nuvalent, Inc. Reports Q1 2025 Financial Results - TipRanks
Nuveen Asset Management LLC Has $6.62 Million Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium - The Globe and Mail
Nuvalent (NUVL) Stock on the Rise: Decoding the 4.7% Surge and Price Potential - Daily Chhattisgarh News
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year By Investing.com - Investing.com Nigeria
Nuvalent’s SWOT analysis: cancer drug developer’s stock faces pivotal year - Investing.com Australia
Deutsche Bank AG Has $2.79 Million Stock Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Shares Acquired by Bank of America Corp DE - Defense World
BNP Paribas Financial Markets Acquires Shares of 17,366 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvalent Inc-Aktie (NUVL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Balcom Alexandra | Chief Financial Officer |
Jul 15 '25 |
Option Exercise |
18.93 |
5,300 |
100,329 |
67,034 |
| Balcom Alexandra | Chief Financial Officer |
Jul 16 '25 |
Sale |
85.10 |
14,700 |
1,250,970 |
61,734 |
| Balcom Alexandra | Chief Financial Officer |
Jul 15 '25 |
Sale |
83.50 |
5,300 |
442,526 |
61,734 |
| Porter James Richard | President and CEO |
Jul 15 '25 |
Option Exercise |
18.93 |
27,000 |
511,110 |
276,062 |
| Porter James Richard | President and CEO |
Jul 15 '25 |
Sale |
82.27 |
27,000 |
2,221,419 |
249,062 |
0.86%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):